학술논문
Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment?
Document Type
Report
Author
Nevola, Riccardo; Russo, Antonio; Scuotto, Samuel; Imbriani, Simona; Aprea, Concetta; Abitabile, Marianna; Beccia, Domenico; Brin, Chiara; Carusone, Caterina; Cinone, Francesca; Cirigliano, Giovanna; Colantuoni, Sara; Cozzolino, Domenico; Cuomo, Giovanna; Del Core, Micol; Gjeloshi, Klodian; Marrone, Aldo; Medicamento, Giulia; Meo, Luciana Agnese; Nappo, Francesco; Padula, Andrea; Pafundi, Pia Clara; Ranieri, Roberta; Ricozzi, Carmen; Rinaldi, Luca; Romano, Ciro Pasquale; Ruocco, Rachele; Ruosi, Carolina; Salvati, Annabella; Sasso, Ferdinando Carlo; Sellitto, Ausilia; Sommese, Pino; Villani, Angela; Coppola, Nicola; Adinolfi, Luigi Elio
Source
Respiratory Research. December 3, 2022, Vol. 23 Issue 1
Subject
Language
English
ISSN
1465-9921
Abstract
Author(s): Riccardo Nevola[sup.1,4] , Antonio Russo[sup.2] , Samuel Scuotto[sup.2] , Simona Imbriani[sup.1] , Concetta Aprea[sup.1] , Marianna Abitabile[sup.1] , Domenico Beccia[sup.1] , Chiara Brin[sup.1] , Caterina Carusone[sup.1] , Francesca Cinone[sup.1] [...]
Background Acute respiratory distress syndrome (ARDS) is one of the most severe complications of SARS-CoV-2 infection. Non-Invasive Respiratory Support (NRS) as Continuous Positive Airway Pressure (CPAP) and/or Non-Invasive Ventilation (NIV) has been proven as effective in the management of SARS-CoV-2-related ARDS. However, the most appropriate timing for start NRS is unknown. Methods We conducted a prospective pilot study including all consecutive patients who developed moderate SARS-CoV-2-related ARDS during hospitalization. Patients were randomly divided into two intervention groups according to ARDS severity (assessed by PaO.sub.2/FiO.sub.2-P/F) at NRS beginning: group A started CPAP/NIV when P/F was [less than or equai to] 200 and group B started CPAP/NIV when P/F was [less than or equai to] 150. Eligible patients who did not give their consent to CPAP/NIV until the severe stage of ARDS and started non-invasive treatment when P/F [less than or equai to] 100 (group C) was added. The considered outcomes were in-hospital mortality, oro-tracheal intubation (OTI) and days of hospitalization. Results Among 146 eligible patients, 29 underwent CPAP/NIV when P/F was [less than or equai to] 200 (Group A), 68 when P/F was [less than or equai to] 150 (Group B) and 31 patients agreed to non-invasive treatment only when P/F was [less than or equai to] 100 (Group C). Starting NRS at P/F level between 151 and 200 did not results in significant differences in the outcomes as compared to treatment starting with P/F ranging 101-150. Conversely, patients undergone CPAP/NIV in a moderate stage (P/F 101-200) had a significantly lower in-hospital mortality rate (13.4 vs. 29.0%, p = 0.044) and hospitalization length (14 vs. 15 days, p = 0.038) than those in the severe stage (P/F [less than or equai to] 100). Age and need for continuous ventilation were independent predictors of CPAP/NIV failure. Conclusions Starting CPAP/NIV in patients with SARS-CoV-2-related ARDS in moderate stage (100 > P/F [less than or equai to] 200) is associated to a reduction of both in-hospital mortality and hospitalization length compared to the severe stage (P/F [less than or equai to] 100). Starting CPAP/NIV with a P/F > 150 does not appear to be of clinical utility. Keywords: SARS-CoV-2, COVID-19, ARDS, CPAP, NIV
Background Acute respiratory distress syndrome (ARDS) is one of the most severe complications of SARS-CoV-2 infection. Non-Invasive Respiratory Support (NRS) as Continuous Positive Airway Pressure (CPAP) and/or Non-Invasive Ventilation (NIV) has been proven as effective in the management of SARS-CoV-2-related ARDS. However, the most appropriate timing for start NRS is unknown. Methods We conducted a prospective pilot study including all consecutive patients who developed moderate SARS-CoV-2-related ARDS during hospitalization. Patients were randomly divided into two intervention groups according to ARDS severity (assessed by PaO.sub.2/FiO.sub.2-P/F) at NRS beginning: group A started CPAP/NIV when P/F was [less than or equai to] 200 and group B started CPAP/NIV when P/F was [less than or equai to] 150. Eligible patients who did not give their consent to CPAP/NIV until the severe stage of ARDS and started non-invasive treatment when P/F [less than or equai to] 100 (group C) was added. The considered outcomes were in-hospital mortality, oro-tracheal intubation (OTI) and days of hospitalization. Results Among 146 eligible patients, 29 underwent CPAP/NIV when P/F was [less than or equai to] 200 (Group A), 68 when P/F was [less than or equai to] 150 (Group B) and 31 patients agreed to non-invasive treatment only when P/F was [less than or equai to] 100 (Group C). Starting NRS at P/F level between 151 and 200 did not results in significant differences in the outcomes as compared to treatment starting with P/F ranging 101-150. Conversely, patients undergone CPAP/NIV in a moderate stage (P/F 101-200) had a significantly lower in-hospital mortality rate (13.4 vs. 29.0%, p = 0.044) and hospitalization length (14 vs. 15 days, p = 0.038) than those in the severe stage (P/F [less than or equai to] 100). Age and need for continuous ventilation were independent predictors of CPAP/NIV failure. Conclusions Starting CPAP/NIV in patients with SARS-CoV-2-related ARDS in moderate stage (100 > P/F [less than or equai to] 200) is associated to a reduction of both in-hospital mortality and hospitalization length compared to the severe stage (P/F [less than or equai to] 100). Starting CPAP/NIV with a P/F > 150 does not appear to be of clinical utility. Keywords: SARS-CoV-2, COVID-19, ARDS, CPAP, NIV